IFM/DFCI 2009 Trial: Role of ASCT, Implications of MRD Status and Comparison of MRI to PET-CT


IFM/DFCI 2009 Trial: Role of ASCT, Implications of MRD Status and Comparison of MRI to PET-CT
Slides from presentations at ASH 2015 and transcribed comments from a recent interview with Noopur Raje, MD (2/10/16)
Attal M et al. Autologous transplantation for multiple myeloma in the era of new drugs: A phase III study of the Intergroupe Francophone du Myelome (IFM/DFCI 2009 trial). Proc ASH 2015;Abstract 391.

Avet-Loiseau H et al. Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial. Proc ASH 2015;Abstract 191.

Moreau P et al. Prospective evaluation of MRI and PET-CT at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial. Proc ASH 2015;Abstract 395.

Dr Raje is Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts.